Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 108

1.

Cross-species models of attention-deficit/hyperactivity disorder and autism spectrum disorder: lessons from CNTNAP2, ADGRL3, and PARK2.

Dalla Vecchia E, Mortimer N, Palladino VS, Kittel-Schneider S, Lesch KP, Reif A, Schenck A, Norton WHJ.

Psychiatr Genet. 2019 Feb;29(1):1-17. doi: 10.1097/YPG.0000000000000211.

PMID:
30376466
2.

The mediating role of phosphodiesterase type 4 in the dopaminergic modulation of motor impulsivity.

Heckman PRA, Blokland A, Van Goethem NP, Van Hagen BTJ, Prickaerts J.

Behav Brain Res. 2018 Sep 17;350:16-22. doi: 10.1016/j.bbr.2018.05.017. Epub 2018 May 17.

3.

Clonidine modulates the activity of the subthalamic-supplementary motor loop: evidence from a pharmacological study combining deep brain stimulation and electroencephalography recordings in Parkinsonian patients.

Spay C, Albares M, Lio G, Thobois S, Broussolle E, Lau B, Ballanger B, Boulinguez P.

J Neurochem. 2018 Aug;146(3):333-347. doi: 10.1111/jnc.14447.

PMID:
29675956
4.

False-Positive Findings on Dopamine Transporter SPECT Due to Therapeutic Dextroamphetamine and Amphetamine.

Frankl JA, Bose S, Kuo PH.

J Nucl Med Technol. 2018 Jun;46(2):149-150. doi: 10.2967/jnmt.117.201558. Epub 2017 Dec 22.

PMID:
29273699
6.

Longitudinal decline of driving safety in Parkinson disease.

Uc EY, Rizzo M, O'Shea AMJ, Anderson SW, Dawson JD.

Neurology. 2017 Nov 7;89(19):1951-1958. doi: 10.1212/WNL.0000000000004629. Epub 2017 Oct 11.

7.

Pedestrian safety in patients with Parkinson's disease: A case-control study.

Ford KJ, Joop A, Memon RA, Wood KH, Ball K, Cutter GR, Schwebel DC, Amara AW.

Mov Disord. 2017 Dec;32(12):1748-1755. doi: 10.1002/mds.27124. Epub 2017 Oct 4.

8.

Manganese and Developmental Neurotoxicity.

Lucchini R, Placidi D, Cagna G, Fedrighi C, Oppini M, Peli M, Zoni S.

Adv Neurobiol. 2017;18:13-34. doi: 10.1007/978-3-319-60189-2_2. Review.

9.

No genetic association between attention-deficit/hyperactivity disorder (ADHD) and Parkinson's disease in nine ADHD candidate SNPs.

Geissler JM; International Parkinson Disease Genomics Consortium members, Romanos M, Gerlach M, Berg D, Schulte C.

Atten Defic Hyperact Disord. 2017 Jun;9(2):121-127. doi: 10.1007/s12402-017-0219-8. Epub 2017 Feb 7.

10.

An objective measure combining physical and cognitive fatigability: Correlation with subjective fatigue in Parkinson's disease.

Martino D, Tamburini T, Zis P, Rosoklija G, Abbruzzese G, Ray-Chaudhuri K, Pelosin E, Avanzino L.

Parkinsonism Relat Disord. 2016 Nov;32:80-86. doi: 10.1016/j.parkreldis.2016.08.021. Epub 2016 Aug 31.

PMID:
27600158
11.

Gamma Oscillations in the Hyperkinetic State Detected with Chronic Human Brain Recordings in Parkinson's Disease.

Swann NC, de Hemptinne C, Miocinovic S, Qasim S, Wang SS, Ziman N, Ostrem JL, San Luciano M, Galifianakis NB, Starr PA.

J Neurosci. 2016 Jun 15;36(24):6445-58. doi: 10.1523/JNEUROSCI.1128-16.2016.

12.

Dysfunction in attentional processing in patients with Parkinson's disease and visual hallucinations.

Hall JM, O'Callaghan C, Shine JM, Muller AJ, Phillips JR, Walton CC, Lewis SJ, Moustafa AA.

J Neural Transm (Vienna). 2016 May;123(5):503-7. doi: 10.1007/s00702-016-1528-3. Epub 2016 Mar 3.

PMID:
26940598
13.

Comorbidity between neurological illness and psychiatric disorders.

Hesdorffer DC.

CNS Spectr. 2016 Jun;21(3):230-8. doi: 10.1017/S1092852915000929. Epub 2016 Feb 22. Review.

PMID:
26898322
14.

Investigation of neuropsychological characteristics of very mild and mild dementia with Lewy bodies.

Petrova M, Pavlova R, Zhelev Y, Mehrabian S, Raycheva M, Traykov L.

J Clin Exp Neuropsychol. 2016;38(3):354-60. doi: 10.1080/13803395.2015.1117058. Epub 2015 Dec 17.

PMID:
26678542
15.

[Developmental Disorders and Dementia].

Midorikawa A.

Brain Nerve. 2015 Sep;67(9):1125-32. doi: 10.11477/mf.1416200271. Review. Japanese.

PMID:
26329153
16.

[The use of buspirone in clinical practice].

Levin OS.

Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(4):83-87. doi: 10.17116/jnevro20151154183-87. Russian.

PMID:
26288293
17.

The impact of neuroscience on society: cognitive enhancement in neuropsychiatric disorders and in healthy people.

Sahakian BJ, Bruhl AB, Cook J, Killikelly C, Savulich G, Piercy T, Hafizi S, Perez J, Fernandez-Egea E, Suckling J, Jones PB.

Philos Trans R Soc Lond B Biol Sci. 2015 Sep 19;370(1677):20140214. doi: 10.1098/rstb.2014.0214. Review.

18.

Paraquat exposure induces behavioral deficits in larval zebrafish during the window of dopamine neurogenesis.

Nellore J, P N.

Toxicol Rep. 2015 Jun 16;2:950-956. doi: 10.1016/j.toxrep.2015.06.007. eCollection 2015.

19.

Impact of mild cognitive impairment on outcome following deep brain stimulation surgery for Parkinson's disease.

Abboud H, Floden D, Thompson NR, Genc G, Oravivattanakul S, Alsallom F, Swa B, Kubu C, Pandya M, Gostkowski M, Cooper S, Machado AG, Fernandez HH.

Parkinsonism Relat Disord. 2015 Mar;21(3):249-53. doi: 10.1016/j.parkreldis.2014.12.018. Epub 2014 Dec 31.

PMID:
25578289
20.

Dopamine midbrain neurons in health and Parkinson's disease: emerging roles of voltage-gated calcium channels and ATP-sensitive potassium channels.

Dragicevic E, Schiemann J, Liss B.

Neuroscience. 2015 Jan 22;284:798-814. doi: 10.1016/j.neuroscience.2014.10.037. Epub 2014 Oct 30. Review.

Supplemental Content

Loading ...
Support Center